B of A Securities Downgrades Neoleukin Therapeutics to Underperform, Announces $1 Price Target
B of A Securities analyst Greg Harrison downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Underperform and announces $1 price target.
HC Wainwright Cuts Price Target On This Stock By 73%, Also Check Out Other Major PT Changes Here
Susquehanna cut the price target on Baidu, Inc. (NASDAQ: BIDU) from $200 to $195. Susquehanna analyst Shyam Patil maintained the stock with a Positive rating. Baidu shares rose 0.7% to $139.38 in pre-market trading.
HC Wainwright & Co. Maintains Buy on Neoleukin Therapeutics, Lowers Price Target to $6
HC Wainwright & Co. analyst Robert Burns maintains Neoleukin Therapeutics (NASDAQ:NLTX) with a Buy and lowers the price target from $22 to $6.
Recap: Neoleukin Therapeutics Q2 Earnings
Neoleukin Therapeutics (NASDAQ:NLTX) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.